Showing 4191-4200 of 8129 results for "".
- Analysis: Mix of Low- and Fair-quality Information for Hidradenitis Suppurativa Treatments on TikTokhttps://practicaldermatology.com/news/complementary-and-alternative-medicine-for-hidradenitis-suppurativa-discussed-on-tiktok-a-cross-sectional-analysis/2462251/Patients getting information on Hidradenitis suppurativa (HS) from TikTok were frequently exposed to low-quality information, a new study suggests. "Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin disease that negatively impacts quality of life," the
- Alvotech and Teva Announce US Approval of Simlandi, a Biosimilar to Humirahttps://practicaldermatology.com/news/alvotech-and-teva-announce-us-approval-of-simlandi-a-biosimilar-to-humira/2462250/Alvotech and Teva Pharmaceuticals announced the FDA approval of Simlandi (adalimumab-ryvk) injection, as an interchangeable biosimilar to blockbuster drug Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as&n
- Biofrontera Announces Restructuring of Supply Agreement, Reduces Ameluz Transfer Pricinghttps://practicaldermatology.com/news/biofrontera-inc-announces-private-placement-of-up-to-160-million-priced-at-market-per-nasdaq-rules/2462246/Biofrontera has announced a restructuring of agreements with its former parent company, Biofrontera AG, aimed at enhancing long-term profitability. As a result, the transfer price of its leading product, Ameluz, indicated for the treatment of actinic keratosis, will be slashed from 50% to 25% for
- FDA Approves First Medication to Treat Severe Frostbitehttps://practicaldermatology.com/news/fda-approves-first-medication-to-treat-severe-frostbite/2462244/The FDA has approved Eicos Sciences' Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation. “This approval provides patients with the first-ever treatment option for severe frostbite,” Norman Stockbridge, MD, PhD
- Galderma Announces Filing Acceptance for Investigational Prurigo Nodularis and AD Treatmenthttps://practicaldermatology.com/news/galderma-announces-filing-recepetion-for-investigational-prurigo-nodularis-treatment/2462243/Galderma announced the acceptance of its Biologics License Applications for nemolizumab, a first-in-class monoclonal antibody IL-31 inhibitor, for the treatment of prurigo nodularis in adults and adolescents with moderate-to-severe atopic dermatitis (AD). The agency, according to a news
- Dermavant Submits Supplemental NDA for VTAMA (tapinarof) Cream, 1% for Atopic Dermatitishttps://practicaldermatology.com/news/dermavant-submits-supplemental-nda-for-vtama-tapinarof-1-cream/2462242/Dermavant announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VTAMA (tapinarof) cream, 1% for treating atopic dermatitis (AD) in adults and children aged 2 years and older. The novel, aryl hydrocarbon receptor antag
- Cutera Announces International Commercial Launch of AviClear for the Treatment of Acnehttps://practicaldermatology.com/news/cutera-announces-international-commercial-launch-of-aviclear-for-the-treatment-of-acne/2462240/Cutera announced the international limited commercial release of AviClear, which the company describes as the first energy-based device FDA-cleared for the long-term treatment of mild, moderate, and severe acne. AviClear is now commercially available, on a limited basis, in the UK, Europe, a
- Federated Learning Comparable to Traditional Learning Methods for AI-based Melanoma Diagnosishttps://practicaldermatology.com/news/federated-learning-comparable-to-traditional-learning-methods-for-ai-based-melanoma-diagnosis/2462238/A decentralized federated learning approach was comparable in diagnostic performance to traditional centralized and ensemble learning methods in AI-based melanoma diagnosis, new research suggests. Study authors conducted a multicentric, single-arm diagnostic study conducted across six Ger
- Analysis: Inconsistent Pretreatment Testing for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/analysis-inconsistent-pretreatment-testing-for-inflammatory-skin-diseases/2462233/A new analysis of US commercial insurance claims databases indicated that less than 60% of people living with chronic inflammatory skin diseases (CISD) receive recommended pretreatment testing.
- Analysis Reveals Pre- and Post-COVID-19 Teledermatology Usage and Barriershttps://practicaldermatology.com/news/teledermatology-platforms-usage-and-barriers-a-cross-sectional-analysis-of-united-states-based-dermatologists-pre-and-post-covid-19/2462231/Dermatologists have increasingly turned to teledermatology to enhance patient care, but a recent study highlights crucial disparities in platform usage and functionality among practitioners. Researchers used cross-sectional pre-validated survey in 2021 and sought to discern va